Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Rare disease

Anaplastic large cell lymphoma T- and null-cell types

  • 7 clinical trials
Quick filters

7 Clinical trials

Primary mediastinal large B-cell lymphoma+3

Recruiting

Study of dapagliflozin to prevent heart complications during lymphoma treatment in patients receiving first-line therapy

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Aalborg University Hospital

Anaplastic large cell lymphoma T- and null-cell types+1

Recruiting

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Brigatinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Anaplastic large cell lymphoma T- and null-cell types+3

Recruiting

Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Crizotinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Anaplastic large cell lymphoma T- and null-cell types

Recruiting

Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Vinblastine Sulfate
  • Sponsor:GPOH gGmbH

Anaplastic large cell lymphoma T- and null-cell types

Not recruiting

Study of Lorlatinib for Patients with ALK+ Anaplastic Large Cell Lymphoma After Ineffective ALK Inhibitor Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lorlatinib
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Anaplastic large cell lymphoma T- and null-cell types

Not recruiting

Study of Nivolumab for Children and Adults with Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Nivolumab
  • Sponsor:Institut Gustave Roussy
See all trials →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.